Instead, oADV treatment appeared to label tumour cells as “non-self”, leading to enhanced MHC-1 and co-stimulatory CD80 expression, and presentation of “non-self” viral epitopes on the tumour-cell surface, triggering an anti-cancer immune response. This evidence concerns the gene CD80 and neoplasm.